Data Reinforce Benefits of Medtronic Cardiac Resynchronization Therapy Technologies in 'Real-World' Setting
May 15 2017 - 11:00AM
EffectivCRT(TM)and
AdaptivCRT(TM) Exclusives Featured in Heart Rhythm 2017
Presentations
DUBLIN - May 15, 2017 -
Medtronic plc (NYSE: MDT) today announced new data supporting the
clinical performance of the company's exclusive EffectivCRT(TM)
Diagnostic and AdaptivCRT(TM) algorithm in heart failure patients
who receive cardiac resynchronization therapy (CRT) devices. The
data were recently presented at Heart Rhythm 2017, the Heart Rhythm
Society's 38th Annual Scientific Sessions in Chicago.
CRT is an established treatment that uses an
implantable defibrillator or pacemaker to improve the pumping
efficiency of the heart. Many CRT devices report "percent pacing" -
a measure of whether the device sends a pacing pulse to stimulate
the heart. However, they do not report the effectiveness of each
pacing stimulus - that is, whether the pacing pulse "captures" the
heart muscle and improves its pumping ability. The EffectivCRT
Diagnostic - available on the newest Medtronic CRT-defibrillators
and CRT-pacemakers - automatically determines the effectiveness of
left ventricular pacing.
Chris Plummer, M.D., of Freeman Hospital,
Newcastle-on-Tyne, United Kingdom, presented an analysis of 335
patients implanted with a Claria MRI(TM) CRT-D SureScan(TM), which
provides diagnostics to help determine the cause of ineffective
pacing. Awareness of effective CRT can help physicians provide a
more personalized approach to treatment.
Additionally, a large (40,000+ patients)
observational study compared the risk of developing atrial
fibrillation (AF) in patients with CRT-Ds treated with AdaptivCRT
vs. standard biventricular pacing. Patients treated with AdaptivCRT
experienced a 35 percent reduction in the subsequent development of
AF compared to patients treated with standard biventricular pacing.
The data presented at Heart Rhythm 2017 are consistent with
previous findings from the randomized Adaptive CRT clinical trial,
which demonstrated a 46 percent reduction in the risk of
developing AF1.
"These outcomes further confirm the benefits of
these advanced cardiac resynchronization therapy technologies
delivered in a contemporary real-world clinical setting," said
Jonathan Hsu, M.D., cardiac electrophysiologist and assistant
professor of medicine at the University of California, San Diego.
"AdaptivCRT gives us more insights and automatically makes
adjustments based on each patient's unique needs, and our study
suggests that its use is associated with a decreased risk of
developing atrial fibrillation."
The AdaptivCRT algorithm, available in the
Medtronic Claria MRICRT-D, Amplia MRI(TM) Quad CRT-D SureScan(TM),
Percepta(TM) Quad CRT-P MRI SureScan(TM), and Serena(TM) Quad CRT-P
MRI SureScan(TM), adjusts the way the device stimulates (paces) the
heart according to minute-to-minute evaluations of each patient's
rhythm. The Percepta Quad CRT-P also features the EffectivCRT
Diagnostic.
"Medtronic is committed to providing the most
advanced technologies that are shown to help improve the delivery
and effectiveness of cardiac resynchronization therapy in both
controlled and real-world environments," said David Steinhaus,
M.D., vice president and general manager of the Heart Failure
business, which is part of the Cardiac and Vascular Group at
Medtronic. "Our portfolio of cardiac devices and technologies
continues to lead the way in personalized care, creating better
solutions and improving individual patient outcomes."
In collaboration with leading clinicians,
researchers and scientists worldwide, Medtronic offers the broadest
range of innovative medical technology for the interventional and
surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services of
the highest quality that deliver clinical and economic value to
healthcare consumers and providers around the world.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 88,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
1 Martin D, et
al. Clinical outcomes with adaptive cardiac resynchronization
therapy: Long-term outcomes of the Adaptive CRT Trial. HFSA Annual
Scientific Meeting. September 23, 2013.
Contacts:
Tracy McNulty
Public Relations
+1-763-526-2492
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024